Levocabastine ophthalmic Pregnancy and Breastfeeding Warnings
Brand names: Livostin
Levocabastine ophthalmic Pregnancy Warnings
Levocabastine has been assigned to pregnancy category C by the FDA. Animal studies at doses 16,500 to 66,000 times the maximum recommended human ocular dose have demonstrated teratogenicity. There are no controlled data in human pregnancy. Levocabastine should only be given during pregnancy when benefit outweighs risk.
Levocabastine ophthalmic Breastfeeding Warnings
Levocabastine is excreted into human milk. In one nursing woman, the daily dose in the infant after maternal ophthalmic instillation was approximately 0.5 mcg. Adverse effects in the infant are unlikely.
See also
References for pregnancy information
- Dechant KL, Goa KL (1991) "Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis." Drugs, 41, p. 202-24
- "Product Information. Livostin (levocabastine ophthalmic)." Ciba Vision Ophthalmics
References for breastfeeding information
- Dechant KL, Goa KL (1991) "Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis." Drugs, 41, p. 202-24
- "Product Information. Livostin (levocabastine ophthalmic)." Ciba Vision Ophthalmics
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
